For this reason, ASCO recently recommended using uPA/PAI-1 expression to guide decision-making for adjuvant systemic therapy in patients diagnosed with ER/PR-positive, HER2-negative, N0 breast cancer [11]. Here, SERPINE1 is linked to breast carcinoma.